GOT2 was downregulated in glioblastoma multiforme (GBM), brain lower-grade glioma (LGG), kidney renal papillary cell carcinoma (KIRP), pan-kidney cohort (KIPAN), prostate adenocarcinoma (PRAD), kidney renal clear cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), thyroid carcinoma (THCA), cholangiocarcinoma (CHOL) (Fig. 8A). Here, GOT2 is linked to prostate adenocarcinoma.